SMAD4 is enriched in adherens junction and cell cycle pathways and has been found to have a potential predictive value for esophageal squamous cell carcinoma in patients receiving neoadjuvant chemoradiotherapy (39) RBL2 and CDKN1B are enhanced in cell cycle pathways. This evidence concerns the gene SMAD4 and esophageal squamous cell carcinoma.